cibenzoline 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 630 | 53267-01-9 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
|
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 24.78 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 86 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 4.10 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 8.60 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.50 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 7.30 hours | Lombardo F, Berellini G, Obach RS |
| S (Water solubility) | 5 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Bocci G, Oprea TI, Benet LZ |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Jan. 1, 1978 | YEAR INTRODUCED |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | C01BG07 | CARDIOVASCULAR SYSTEM CARDIAC THERAPY ANTIARRHYTHMICS, CLASS I AND III Other antiarrhythmics, class I and III |
| MeSH PA | D000889 | Anti-Arrhythmia Agents |
| MeSH PA | D002317 | Cardiovascular Agents |
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 12.1 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Potassium voltage-gated channel subfamily H member 2 | Ion channel | IC50 | 5.06 | CHEMBL | |||||
| ATP-sensitive inward rectifier potassium channel 11 | Ion channel | WOMBAT-PK | |||||||
| Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 | Ion channel | IC50 | 4.33 | WOMBAT-PK |
External reference:
| ID | Source |
|---|---|
| D01455 | KEGG_DRUG |
| 21099 | RXNORM |
| C0055720 | UMLSCUI |
| CHEBI:135083 | CHEBI |
| CHEMBL87045 | ChEMBL_ID |
| DB13358 | DRUGBANK_ID |
| C032151 | MESH_SUPPLEMENTAL_RECORD_UI |
| 2747 | PUBCHEM_CID |
| 100678-32-8 | SECONDARY_CAS_RN |
| 004286 | NDDF |
| 004287 | NDDF |
| 719682001 | SNOMEDCT_US |
| 735065001 | SNOMEDCT_US |
| CHEMBL2106074 | ChEMBL_ID |
| 4568 | INN_ID |
| Z7489237QT | UNII |
Pharmaceutical products:
None